371 related articles for article (PubMed ID: 16860179)
21. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
22. Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease.
Balkrishnan R; Christensen DB
Clin Ther; 2000 Apr; 22(4):452-69. PubMed ID: 10823366
[TBL] [Abstract][Full Text] [Related]
23. Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients?
Sin DD; Man SF
Curr Opin Pulm Med; 2007 Mar; 13(2):90-7. PubMed ID: 17255798
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacologic therapy for patients with stable chronic obstructive pulmonary disease--emphasis on inhaled agents].
Nishimura K; Ikeda A; Koyama H; Tsukino M; Hajiro T; Izumi T
Nihon Kyobu Shikkan Gakkai Zasshi; 1996 Dec; 34 Suppl():75-8. PubMed ID: 9216189
[TBL] [Abstract][Full Text] [Related]
25. Impact of a criteria-based reimbursement policy on the use of respiratory drugs delivered by nebulizer and health care services utilization in Nova Scotia, Canada.
Kephart G; Sketris IS; Bowles SK; Richard ME; Cooke CA
Pharmacotherapy; 2005 Sep; 25(9):1248-57. PubMed ID: 16164398
[TBL] [Abstract][Full Text] [Related]
26. Medications for COPD: a review of effectiveness.
Grimes GC; Manning JL; Patel P; Via RM
Am Fam Physician; 2007 Oct; 76(8):1141-8. PubMed ID: 17990836
[TBL] [Abstract][Full Text] [Related]
27. Inhaled drugs as risk factors for community-acquired pneumonia.
Almirall J; Bolíbar I; Serra-Prat M; Palomera E; Roig J; Hospital I; Carandell E; Agustí M; Ayuso P; Estela A; Torres A;
Eur Respir J; 2010 Nov; 36(5):1080-7. PubMed ID: 20525710
[TBL] [Abstract][Full Text] [Related]
28. Guidelines and realities of asthma management. The Philadelphia story.
Lang DM; Sherman MS; Polansky M
Arch Intern Med; 1997 Jun; 157(11):1193-200. PubMed ID: 9183230
[TBL] [Abstract][Full Text] [Related]
29. Impact of regular inhaled corticosteroid use on chronic obstructive pulmonary disease outcomes.
Vollmer WM; Peters D; Crane B; Kelleher C; Buist AS
COPD; 2007 Jun; 4(2):135-42. PubMed ID: 17530507
[TBL] [Abstract][Full Text] [Related]
30. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[TBL] [Abstract][Full Text] [Related]
31. Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants.
Wang PS; Patrick AR; Dormuth C; Maclure M; Avorn J; Canning CF; Schneeweiss S
J Ment Health Policy Econ; 2010 Mar; 13(1):37-44. PubMed ID: 20571181
[TBL] [Abstract][Full Text] [Related]
32. Status of inhalation therapy in bronchial asthma in adults above twelve years of age in armed forces.
Barthwal MS; Deoskar RB; Rajan KE
J Assoc Physicians India; 2005 Aug; 53():681-4. PubMed ID: 16398075
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
Schneeweiss S; Walker AM; Glynn RJ; Maclure M; Dormuth C; Soumerai SB
N Engl J Med; 2002 Mar; 346(11):822-9. PubMed ID: 11893794
[TBL] [Abstract][Full Text] [Related]
34. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.
Breekveldt-Postma NS; Koerselman J; Erkens JA; Lammers JW; Herings RM
Respir Med; 2007 Jul; 101(7):1398-405. PubMed ID: 17368011
[TBL] [Abstract][Full Text] [Related]
35. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes.
Cole JA; Norman H; Weatherby LB; Walker AM
Pharmacotherapy; 2006 Aug; 26(8):1157-64. PubMed ID: 16863491
[TBL] [Abstract][Full Text] [Related]
36. The impact of pharmacotherapy policy: a case study.
Tamblyn R
Can J Clin Pharmacol; 2001; 8 Suppl A():39A-44A. PubMed ID: 11586378
[TBL] [Abstract][Full Text] [Related]
37. Impact of prescription coverage on hospital and physician costs: a case study of medicare beneficiaries with chronic obstructive pulmonary disease.
Stuart B; Doshi JA; Briesacher B; Wrobel MV; Baysac F
Clin Ther; 2004 Oct; 26(10):1688-99. PubMed ID: 15598486
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies.
Suissa S
Am J Respir Crit Care Med; 2003 Jul; 168(1):49-53. PubMed ID: 12663327
[TBL] [Abstract][Full Text] [Related]
39. Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes.
Hanania NA
Clin Ther; 2007 Oct; 29(10):2121-33. PubMed ID: 18042470
[TBL] [Abstract][Full Text] [Related]
40. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
Sobieraj DM; White CM; Coleman CI
Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
